Functional properties of glycine receptors expressed in primary cultures of mouse cerebellar granule cells

Neuroscience
L ElsterP Wahl

Abstract

Expression of the glycine receptor was investigated in membranes prepared from primary cultures of mouse cerebellar granule cells and postnatal mouse cerebellum using the antagonist [3H]strychnine for ligand binding. Scatchard analysis of the binding data obtained from P17 cerebellum showed a single population of binding sites (K(D) approximately 6 nM) and [3H]strychnine binding to membranes prepared from cultured neurons and P17 cerebellum was found to have the same sensitivity to the glycinergic agonists glycine, beta-alanine and taurine. The development of [3H]strychnine binding sites in cultured cerebellar granule cells and cerebellum showed opposing profiles. [3H]strychnine binding to primary cultures increased significantly during the culture period whereas during development in vivo the number of binding sites decreased over time and was hardly detectable in the adult cerebellum. Release of preloaded D-[3H]aspartate evoked by 40 mM K+ from granule cells cultured for seven days was inhibited by glycine by about 50%. Beginning after seven days in culture the ability of glycine to inhibit transmitter release declined to no inhibition after 17 days in culture. Experiments with the non-competitive antagonist, picrotoxinin, sh...Continue Reading

References

Jan 1, 1990·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·B BelhageA Schousboe
Nov 26, 1990·European Journal of Biochemistry·D LangoschH Betz
May 22, 1985·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·S G Cull-Candy, D C Ogden
Sep 1, 1989·The Journal of Physiology·R Miledi, R M Woodward
Aug 1, 1989·Neurochemical Research·J Drejer, A Schousboe
Jul 22, 1988·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·M K CarpenterR Miledi
Nov 10, 1987·European Journal of Pharmacology·J Drejer, T Honoré
Oct 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·A B Young, S H Snyder
Oct 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·A B Young, S H Snyder
Sep 28, 1968·Nature·J S Kelly, K Krnjević
Dec 1, 1984·The Journal of Physiology·R Miledi, I Parker
Jul 22, 1982·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·R Miledi
Aug 1, 1981·Pflügers Archiv : European journal of physiology·O P HamillF J Sigworth
Oct 30, 1981·Biochemical and Biophysical Research Communications·D GrahamH Betz
Apr 5, 1983·European Journal of Biochemistry·D GrahamH Betz
Jul 1, 1982·The Journal of Physiology·K KusanoJ Stinnakre
Jan 1, 1994·Journal of Physiology, Paris·H BetzN Rundström
Jun 1, 1994·Journal of Neurochemistry·P WahlA Schousboe
Mar 26, 1993·Brain Research·C M BeckerH Schröder
Jan 2, 1997·Brain Research. Developmental Brain Research·C Virginio, E Cherubini

❮ Previous
Next ❯

Citations

Aug 28, 1999·Neuropharmacology·B David-WatineP Bregestovski
Nov 3, 2001·The Journal of Physiology·M NeunlistM Schemann
Feb 2, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Peter D YimCharles W Emala

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.